MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: MedTech
MedTech

$5 Billion Bet: Isomorphic Labs Shatters AI Drug Discovery Funding Records Amid Industry Pivot to Clinical Validation

MedXY Editorial TeamNov 19, 2026

In a landmark move that underscores Silicon Valley and global sovereign wealth funds’ enduring conviction in artificial intelligence, Alphabet-backed AI drug discovery firm Isomorphic Labs announced on November 17 that it has closed a $5 billion Series C funding round.

Co-led by Greenoaks and Sequoia Capital, the round saw new participation from Andreessen Horowitz (a16z) alongside a substantial follow-on investment from parent company Alphabet. Existing backers, including Temasek, MGX, and the UK Sovereign AI Fund, also joined the financing. The raise sets a new all-time record for a single funding round in the AI-driven pharmaceutical sector, bringing Isomorphic Labs’ total publicly disclosed capital to $7.7 billion since its debut external raise in March 2025.

High Valuation, Zero Clinical Candidates

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Google DeepMind Unveils AlphaGenome 2, Bridging Single-Cell Biology and Genetics to Accelerate Rare Disease and Oncology Breakthroughs

MedTechNov 12, 2026

Biohub's $1.8B Virtual Biology Push Moves AI Drug Discovery's Bottleneck to Data

MedTechOct 9, 2026

APLMS Launches S.C.I. Healthy Longevity Model Across Singapore, China, and India

MedTechOct 5, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story